| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.0021 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | avicin D | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |